Citius Oncology Inc. (CTOR) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Citius Oncology Inc. (CTOR:NASDAQ), powered by AI.

Current Price
$0.66
P/E Ratio
-2.0
Market Cap
49M
Sector
Healthcare
What is the Citius Oncology Inc. stock price forecast?

Citius Oncology Inc. is currently trading at $0.66. View real-time AI analysis on Alpha Lenz.

What is Citius Oncology Inc. insider trading activity?

View the latest insider trading data for Citius Oncology Inc. on Alpha Lenz.

What is Citius Oncology Inc.'s P/E ratio?

Citius Oncology Inc.'s P/E ratio is -2.0.

Citius Oncology Inc.

NASDAQ · CTOR
$0.66-0.03(-4.18%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Citius Oncology Inc.'s future dividend policy...
Alpha Chat Insight

Citius Oncology Inc. trades at a P/E of -2.0 (undervalued) with modest ROE of -54.4%.

Ask for details

Company Overview

Citius Oncology Inc. operates as a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for cancer treatment. The primary function of Citius Oncology is to research and develop innovative therapies that aim to enhance the efficacy and safety profiles of current cancer treatments. The company focuses on leveraging new technology platforms and scientific advancements to address unmet medical needs in various types of cancer, impacting both the oncology and pharmaceutical sectors. Citius Oncology's significance in the market revolves around its commitment to advancing cancer therapeutics, which is a critical area due to the disease's widespread impact globally. As a clinical-stage entity, the company plays a crucial role in the pipeline of medical innovation, contributing to potential future options for cancer care. Citius Oncology partners with research institutions and other biopharmaceutical enterprises to push the boundaries of standard oncology treatments. This makes it an influential player in the biotechnology and healthcare sectors, aligning with a broader industry goal to improve patient outcomes in oncology.

CEOMr. Leonard L. Mazur
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2025

Profile

$48.65MMarket Cap
$0.00Revenue
0.00Shares Out
0Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-1.96P/E
1.08P/B
N/AEV/Sales
-2.07EV/EBITDA
-4.33P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-26.72%ROA
-54.42%ROE
-25.35%ROIC

Financial Health

$3.92MCash & Cash Equivalents
$52.15MNet Debt
124.99%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Citius Oncology Inc. (ticker: CTOR) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $49M.

The current price is $0.664 with a P/E ratio of -1.96x and P/B of 1.08x.

ROE is -54.42%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Citius Oncology Inc. (CTOR) Stock Forecast 2026 $0.66 — Price, Financials & Analyst Targets | Alpha Lenz